ID   1A9PTX22
AC   CVCL_H621
SY   1A9/PTX22; 1A9/ptx-22; 1A9/Ptx-22; PTX22
DR   cancercelllines; CVCL_H621
DR   ChEMBL-Cells; CHEMBL3308076
DR   ChEMBL-Targets; CHEMBL613858
DR   PubChem_Cell_line; CVCL_H621
DR   Wikidata; Q54582757
RX   PubMed=9202030;
RX   PubMed=10871860;
WW   https://cornell.flintbox.com/technologies/e7fac129-74ae-48d1-ab1c-9f087b79ddd7
CC   Population: African American.
CC   Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
CC   Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_H619 ! A2780-1A9
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 05-10-23; Version: 20
//
RX   PubMed=9202030; DOI=10.1074/jbc.272.27.17118;
RA   Giannakakou P., Sackett D.L., Kang Y.-K., Zhan Z.-R., Buters J.T.M.,
RA   Fojo T., Poruchynsky M.S.;
RT   "Paclitaxel-resistant human ovarian cancer cells have mutant
RT   beta-tubulins that exhibit impaired paclitaxel-driven polymerization.";
RL   J. Biol. Chem. 272:17118-17125(1997).
//
RX   PubMed=10871860; DOI=10.1038/sj.onc.1203642;
RA   Giannakakou P., Poy G., Zhan Z.-R., Knutsen T., Blagosklonny M.V.,
RA   Fojo T.;
RT   "Paclitaxel selects for mutant or pseudo-null p53 in drug resistance
RT   associated with tubulin mutations in human cancer.";
RL   Oncogene 19:3078-3085(2000).
//